Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

3 Experimental Cancer Drugs Investors Should Be Closely Watching

By Cheryl Swanson - Jul 2, 2015 at 4:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Meet the drugs our experts believe have shown the most promising results in the race to cure cancer.

Source: Photo courtesy of Flickr, Creative Commons.

Oncology is the most crowded area of drug research, so there's a bevy of companies trying to come out on top. But the FDA also awards "breakthrough" status for expedited development for treatments in cancer more than any other field.

We asked three Motley Fool experts to hone in on cancer drugs that are now zipping through trials, which could someday prolong the lives of patients. While the failure rate for drugs and vaccines is very high, all the candidates below have shown striking results. Any or all of them could not only help investors score gains, but could eventually turn some cancers from death sentences into manageable chronic illnesses.

Sean Williams: Whether you realize it or not, global cancer drug spending topped $100 billion in 2014, and it could grow to as much as $147 billion by 2018 according to IMS Institute for Healthcare Informatics. For cancer patients, it means potentially game-changing therapies are on the way. For investors, it could mean the opportunity to piggyback on some life-saving medicines.

One cancer drug that I'd suggest investors closely monitor is Geron's ( GERN 9.09% ) imetelstat, which is targeted at treating myelofibrosis, a rare form of bone marrow cancer that leads to scarring. Currently, there is just one approved myelofibrosis therapy in the United States: Incyte's Jakafi.

Jakafi is a JAK2 inhibitor that's been shown to provide clinical improvement in studies, such as in spleen volume reduction and hematocrit control, but it does not produce partial or complete responses in patients. In other words, it strictly minimizes patient symptoms to improve quality of life.

Geron's imetelstat could change the game. In prior clinical studies, both partial and complete responses were observed in myelofibrosis patients. The downside to imetelstat? It comes with possible liver safety concerns, as the Food and Drug Administration halted studies on the experimental drug between mid-March 2014 and early Nov. 2014. Geron is obviously free to advance the drug now with the hold lifted, but its safety concerns still echo loud and clear.

What makes matters even more intriguing is that healthcare conglomerate Johnson & Johnson is betting up to $935 million on Geron that imetelstat will displace JAK2 inhibitors in the future. It paid Geron $35 million upfront in a collaborative deal this past November, and will deliver $900 million more in undisclosed development, regulatory, and sales milestones.

Imetelstat has serious backers; now it's just a matter of whether or not it works in larger studies.

Todd Campbell: Juno Therapeutics ( JUNO ) is developing immuno-oncology drugs that reengineer a patient's T-cells to more easily discover and destroy cancer cells. If Juno Therapeutics approach succeeds, it could end up reducing, or eliminating, the use of chemotherapy in cancer patients.

Juno Therapeutics approach is so intriguing that Celgene Corp is spending $850 million to acquire a 9.1 million shares in the company and handing over another $150 million in cash up front in order to partner with Juno Therapeutics on immunotherapies for cancer and autoimmune disease.

Celgene's interest was likely piqued by Juno Therapeutics' JCAR015, a treatment for blood cancer such as acute lymphoblastic leukemia, or ALL. In early stage trials, 87% of adult ALL patients taking JCAR015 went into complete remission.

Those are impressive results, but investors should remember that most cancer drugs fail in the clinic, and that because this was an early stage trial involving only a small number of people, there's no guarantee that this success will be confirmed in future trials. Regardless, Celgene's partnership and JCAR015's potential makes this one that should be on your radar.

Cheryl Swanson: Brain cancer is a tough disease to beat, but the story may be changing for those who have one of the most common types of brain tumors called glioblastoma. Clinical-stage biotech Celldex Therapeutics ( CLDX 6.45% ) has an experimental drug for this very aggressive cancer; with positive new phase 2 survival data just released, the company could eventually have a winner.

At the American Society of Clinical Oncology's annual meeting last weekend, Celldex released data showing a clear survival benefit for its drug Rintega. The brain-cancer vaccine was awarded the breakthrough designation a few months ago, which could pave the way for an accelerated approval. At twelve months, the ReACT trial data showed that 45% of Rintega patients were alive, versus 31% of control patients. At 18 months, 30% of Rintega patients were alive, versus 15% of control patients.    

Phase 3 data for Rintega is coming later this year. Meanwhile, Northwest Biotherapeutics has a competing glioblastoma candidate called DCVax-L. In contrast to the much more popular CAR-T treatments under development, there's been a lot of uncertainty about cancer vaccines over the years.

But being the dark horses in the race for a cure for cancer has kept the wraps on the prices of these stocks. If positive data continues to come out about their effectiveness, that could sway the critics, and reignite the climb of these two small-cap biotechs.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celldex Therapeutics, Inc. Stock Quote
Celldex Therapeutics, Inc.
CLDX
$38.77 (6.45%) $2.35
Geron Corporation Stock Quote
Geron Corporation
GERN
$1.44 (9.09%) $0.12
Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.
JUNO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.